TGFB1 and cancer: Indeed, neutralizing antibodies to TGFβ, inhibitors to TGFβ Receptor I (TβRI), antisense nucleotides and ligand traps (for TGFβ and other family members) are currently in clinical trial for the treatment of human cancers making them easily transferable to the context of B-ALL.